Table 1 Characteristics of the studies included in the meta-analysis
Author (year) | Region | Type | Actinomycin D-based regimen | Methotrexate-based regimen | ||||
|---|---|---|---|---|---|---|---|---|
Treatment | No. | CR | Treatment | No. | CR | |||
Kang (2019) | China | RCT | Act-D, IV, 10 μg/kg daily for 5 days | 49 | 43 | MTX, IM, 0.4 mg/kg daily for 5 days | 49 | 41 |
Yarandi (2016) | Iran | RCT | Act-D, IV, 1.25 mg/m2 biweeklyAct-D, IV, 1.25 mg/m2 biweekly | 30 | 24 | MTX, IV, 0.4 mg/kg daily for 5 days | 32 | 25 |
Shahbazian (2014) | Iran | RCT | Act-D, IV, 1.25 mg/m2 biweeklyAct-D, IV, 1.25 mg/m2 biweekly | 15 | 13 | MTX, IM, 40 mg/m2 weeklyMTX, IM, 40 mg/m2 weekly | 15 | 8 |
Mousavi (2012) | Iran | RCT | Act-D, IV, 1.25 mg/m2 biweeklyAct-D, IV, 1.25 mg/m2 biweekly | 50 | 45 | MTX, IM, 0.4 mg/kg daily for 5 days | 25 | 17 |
Lertkhachonsuk (2009) | Thailand | RCT | Act-D, IV, 10 μg/kg daily for 5 days | 20 | 20 | MTX, IM, 1 mg/kg on days 1, 3, 5 and 7 + FA, IM, 0.1 mg/kg on days 2, 4, 6 and 8 | 19 | 14 |
Osborne (2011) | Multi-nation | RCT | Act-D, IV, 1.25 mg/m2 biweeklyAct-D, IV, 1.25 mg/m2 biweekly | 109 | 76 | MTX, IM, 30 mg/m2 weeklyMTX, IM, 30 mg/m2 weekly | 107 | 57 |
Gilani (2005) | Iran | RCT | Act-D, IV, 1.25 mg/m2 biweeklyAct-D, IV, 1.25 mg/m2 biweekly | 18 | 16 | MTX, IM, 30 mg/m2 weeklyMTX, IM, 30 mg/m2 weekly | 28 | 14 |
Schink (2020) | U.S. | RCT | Act-D, IV, 1.25 mg/m2 biweeklyAct-D, IV, 1.25 mg/m2 biweekly | 28 | 22 | MTX, IV, 0.4 mg/kg daily for 5 days | 26 | 23 |
Verhoef (2017) | Netherlands | Non-RCT | Act-D, IV, 1.25–2 mg/m2 biweeklyAct-D, IV, 1.25–2 mg/m2 biweekly | 34 | 29 | MTX, IM, 50 mg biweekly | 4 | 1 |
Al-Husaini (2014) | Arabia | Non-RCT | Act-D, IV, 1.25 mg/m2 biweekly or Act-D, IV, 0.5 mg daily for 5 daysAct-D, IV, 1.25 mg/m2 biweekly or Act-D, IV, 0.5 mg daily for 5 days | 23 | 20 | MTX, IM, 1 mg/kg weekly or MTX, IM, 1 mg/kg on days 1, 3, 5 and 7 | 73 | 39 |
Uberti (2015) | Brazil | Non-RCT | Act-D, IV, 1.25–2 mg/m2 biweekly | 79 | 53 | MTX, IM, 1 mg/kg on days 1, 3, 5 and 7 + FA, Oral, 15 mg on days 2, 4, 6 and 8 | 115 | 87 |
Abrao (2008) | Brazil | Non-RCT | Act-D, IV, 12 μg/kg daily for 5 days | 42 | 30 | MTX, IM, 20 mg/m2 daily for 5 daysMTX, IM, 20 mg/m2 daily for 5 days | 42 | 29 |
Yarandi (2008) | Iran | Non-RCT | Act-D, IV, 1.25 mg/m2 biweeklyAct-D, IV, 1.25 mg/m2 biweekly | 50 | 45 | MTX, IM, 30 mg/m2 weeklyMTX, IM, 30 mg/m2 weekly | 81 | 39 |
Baptista (2012) | Brazil | Non-RCT | Act-D, IV, 12 μg/kg daily for 5 days | 20 | 18 | MTX, IM, 50 mg + FA, oral, 15 mg, for 8 days | 20 | 10 |
Lee (2017) | South Korea | Non-RCT | Act-D, IV, 1.25 mg/m2 biweekly or Act-D, IV, 12 μg/kg daily for 5 days | 18 | 15 | MTX, IM, 1 mg/kg on days 1, 3, 5 and 7 + FA, IM, 0.1 mg/kg on days 2, 4, 6 and 8 or MTX, IM, 50 mg/m2 weekly | 53 | 33 |
Matsui (2005) | Japan | Non-RCT | Act-D, IV, 8.5-10μg/kg daily for 5 days | 26 | 20 | MTX, IM, 0.35–0.4 mg/kg daily for 5 days | 133 | 91 |
Matsui (2005) | Japan | Non-RCT | Act-D, IV, 8.5-10μg/kg daily for 5 days | 26 | 20 | MTX, IM, 0.85-1 mg/kg on days 1, 3, 5 and 7 + FA, IM, 85-100μg/kg on days 2, 4, 6 and 8 | 24 | 14 |
Matsui (1998) | Japan | Non-RCT | Act-D, IV, 8.5-10μg/kg daily for 5 days | 25 | 21 | MTX, IM, 0.35–0.4 mg/kg daily for 5 days | 121 | 89 |
Matsui (1998) | Japan | Non-RCT | Act-D, IV, 8.5-10μg/kg daily for 5 days | 25 | 21 | MTX, IM, 0.85-1 mg/kg on days 1, 3, 5 and 7 + FA, IM, 85-100μg/kg on days 2, 4, 6 and 8 | 20 | 12 |